Treatment of metastatic colorectal cancer in mice with CoFactor® in combination with Uftoral® (UFT) as demonstrated by clinical data recently reported by ADVENTRX Pharmaceuticals, Inc. (Amex: ANX).
CoFactor® is a folate-based drug designed to improve the efficacy and safety of the anticancer agent 5-fluorouracil (5-FU) while UFT is an oral anticancer drug approved for use in Asia and Europe that delivers a combination of tegafur, a prodrug of 5-FU, and uracil.
According to Evan M. Levine, ADVENTRX Pharmaceuticals, Inc.’s CEO:
"These CoFactor/UFT results are further evidence of CoFactor's improved ability over leucovorin to potentiate the efficacy of fluoropyrimidines. Results from numerous preclinical studies with and without the addition of oxaliplatin, anti-VEGF or gemcitabine suggest that CoFactor is more effective than leucovorin at modulating 5-FU, thereby increasing inhibition of tumor growth in colorectal, gastric and pancreatic tumor models while demonstrating reduced toxicity."
These results were presented as an abstract entitled: "5,10 Methylenetetrahydrofolate (CoFactor) Enhances UFT Antitumor Activity Against Human Colorectal HT-29 Tumor Xenografts in Nude Mice", at a joint meeting of the 7th International Conference of Asian Clinical Oncology Society (ACOS) & the 9th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) held September 16, 2006 in Beijing, China.
Find more details of the study in the press release.
Comment Preview